Exosome Diagnostics Inc:医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Exosome Diagnostics Inc - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7015
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Exosome Diagnostics Inc (Exosome Diagnostics) is a provider of diagnostic solutions. The company develops, designs, manufactures and markets biofluid-based molecular diagnostic tests and products for use in personalized medicine. Exosome Diagnostics’ services comprise miRNA profiling, mRNA profiling, mutation detection, ribonucleic acid (RNA) sequencing (including full RNA seq) and custom assay development services. The company also offers disease detection, diagnosis, treatment and monitoring. Its technology is used in the treatment of brain cancer, prostate cancer, and Alzheimer’s disease. Exosome Diagnostics is headquartered in Waltham, Massachusetts the US.

Exosome Diagnostics Inc – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Exosome Diagnostics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Exosome Diagnostics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Exosome Diagnostics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Exosome Diagnostics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Exosome Diagnostics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Exosome Diagnostics Inc, Medical Equipment, Deal Details 12
Venture Financing 12
Exosome Diagnostics Raises USD60 Million in Series B Financing Round 12
Exosome Diagnostics Raises Additional USD17.6 Million in Series B Financing 14
Exosome Diagnostics Raises USD1.5 Million in Financing Round 15
Exosome Diagnostics to Raise USD25 Million in Venture Financing 16
Exosome Diagnostics Raises US$27 Million In Series B Financing Round 17
Exosome Diagnostics Raises US$7 Million In Venture Financing 19
Exosome Diagnostics Raises USD3 Million in Venture Financing 20
Partnerships 21
Exosome Diagnostics Enters into Agreement with Intezyne 21
Exosome Diagnostics Enters into Agreement with Merck 22
Exosome Diagnostics Enters into Agreement with Amgen 23
Exosome Diagnostics Enters into Agreement with Takeda Pharma 24
Exosome Diagnostics Enters into Agreement with Addario Lung Cancer Medical Institute 25
Qiagen And Exosome Diagnostics Enter Into Agreement To Develop Diagnostics For Cancer Biomarkers 26
Exosome Diagnostics Enters Into Agreement With Eli Lilly To Discover Biomarker 27
Exosome Diagnostics Enters Into Research Agreement With Mount Sinai Hospital 28
Exosome Diagnostics And Qiagen Enter Into Agreement To Develop Line Of Biofluid Nucleic Acid Kits 29
Exosome Diagnostics Enters Into Co-Development Agreement With Promega For Urine Clinical Sample Concentrator Kit 30
Exosome Diagnostics Enters Into Technology Integration Agreement With Life Technologies 31
Acquisition 32
Bio-Techne Acquires Exosome Diagnostics 32
Exosome Diagnostics Inc – Key Competitors 33
Exosome Diagnostics Inc – Key Employees 34
Exosome Diagnostics Inc – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Strategy And Business Planning 36
Aug 01, 2017: Exosome Diagnostics Announces New World Headquarters and Laboratory in Waltham, MA 36
Corporate Communications 37
Mar 21, 2018: Exosome Diagnostics Names Grannum Sant As Head Of Medical Affairs 37
Legal and Regulatory 38
Jun 13, 2018: Exosome Diagnostics Receives ISO 13485:2016 Certification 38
Aug 03, 2017: Exosome Diagnostics Achieves ISO 13485 Certification 39
Jan 18, 2017: Exosome Diagnostics Obtains ISO 15189 for Its Munich Laboratory 40
Product News 41
May 22, 2018: Exosome Diagnostics Announces Bladder Cancer Surveillance Panel 41
May 15, 2018: Exosome Diagnostics Presents Breakthrough Data Highlighting Tumor Derived RNA in Biofluids at the International Society for Extracellular Vesicles in Spain 42
Apr 17, 2018: Exosome Diagnostics Obviates Tissue Biopsies 43
Oct 11, 2017: Exosome Diagnostics to Present a Novel Atlas of Exosomal mRNA and Long non-coding RNA Across Biofluids at American Society of Exosomes and Microvesicles Annual Meeting 44
Jun 22, 2017: Exosome Diagnostics Presents Breakthrough Liquid Biopsy Technologies at BIO International Convention 45
Other Significant Developments 46
Aug 24, 2017: CareFirst BlueCross BlueShield and Exosome Diagnostics Announce Evidence Development Collaboration for Molecular Diagnostic Tests 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Exosome Diagnostics Inc, Medical Equipment, Key Facts 2
Exosome Diagnostics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Exosome Diagnostics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Exosome Diagnostics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Exosome Diagnostics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Exosome Diagnostics Inc, Deals By Market, 2012 to YTD 2018 9
Exosome Diagnostics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Exosome Diagnostics Raises USD60 Million in Series B Financing Round 12
Exosome Diagnostics Raises Additional USD17.6 Million in Series B Financing 14
Exosome Diagnostics Raises USD1.5 Million in Financing Round 15
Exosome Diagnostics to Raise USD25 Million in Venture Financing 16
Exosome Diagnostics Raises US$27 Million In Series B Financing Round 17
Exosome Diagnostics Raises US$7 Million In Venture Financing 19
Exosome Diagnostics Raises USD3 Million in Venture Financing 20
Exosome Diagnostics Enters into Agreement with Intezyne 21
Exosome Diagnostics Enters into Agreement with Merck 22
Exosome Diagnostics Enters into Agreement with Amgen 23
Exosome Diagnostics Enters into Agreement with Takeda Pharma 24
Exosome Diagnostics Enters into Agreement with Addario Lung Cancer Medical Institute 25
Qiagen And Exosome Diagnostics Enter Into Agreement To Develop Diagnostics For Cancer Biomarkers 26
Exosome Diagnostics Enters Into Agreement With Eli Lilly To Discover Biomarker 27
Exosome Diagnostics Enters Into Research Agreement With Mount Sinai Hospital 28
Exosome Diagnostics And Qiagen Enter Into Agreement To Develop Line Of Biofluid Nucleic Acid Kits 29
Exosome Diagnostics Enters Into Co-Development Agreement With Promega For Urine Clinical Sample Concentrator Kit 30
Exosome Diagnostics Enters Into Technology Integration Agreement With Life Technologies 31
Bio-Techne Acquires Exosome Diagnostics 32
Exosome Diagnostics Inc, Key Competitors 33
Exosome Diagnostics Inc, Key Employees 34
Exosome Diagnostics Inc, Subsidiaries 35

List of Figures
Exosome Diagnostics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Exosome Diagnostics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Exosome Diagnostics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Exosome Diagnostics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Exosome Diagnostics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Exosome Diagnostics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Exosome Diagnostics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Exosome Diagnostics Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[Exosome Diagnostics Inc:医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Alert Logic Inc:企業の戦略的SWOT分析
    Alert Logic Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Aduro BioTech Inc (ADRO):企業の財務・戦略的SWOT分析
    Aduro BioTech Inc (ADRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Ambrx Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Ambrx Inc (Ambrx) is a biopharmaceutical company that offers discovery and development of protein-based medicines by using its expanded genetic code. The company provides pipeline product candidate’s portfolio such as ARX618 FGF21, PSMA ADC, CD70 ADC and Anti-CD3 X Folate. It develops pipeli …
  • Fluor Corporation (FLR):電力:M&Aディール及び事業提携情報
    Summary Fluor Corporation (Fluor) is a provider of engineering and construction services. The company's service portfolio includes design, engineering, procurement, fabrication, modularization, construction, commissioning and maintenance, and project management solutions. Fluor also offers other ser …
  • SDL plc (SDL):企業の財務・戦略的SWOT分析
    Summary SDL Plc (SDL) is a technology solution provider that offers language translation technology, services, and content management services. The company’s products include live content architect, live content create, media manager, idiom world server, campaign analytics, email manager, language w …
  • SQI Diagnostics Inc (SQD):企業の製品パイプライン分析2018
    Summary SQI Diagnostics Inc (SQI Diagnostics) is a diagnostic company that offers in vitro diagnostic and pharmaceutical research products. The company’s products comprise sqidworks, sqidlite and sqid-X. Its sqidworks system is used in labs. SQI Diagnostic’s sqidlite is a practical benchtop system. …
  • Rush Enterprises, Inc.
    Rush Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report Summary Rush Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Fauji Fertilizer Co Ltd (FFC):企業の財務・戦略的SWOT分析
    Fauji Fertilizer Co Ltd (FFC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Larsen & Toubro Infotech Ltd (LTI):企業の財務・戦略的SWOT分析
    Larsen & Toubro Infotech Ltd (LTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Panalpina World Transport (Holding) Ltd.
    Panalpina World Transport (Holding) Ltd. - Strategy, SWOT and Corporate Finance Report Summary Panalpina World Transport (Holding) Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Capitol Federal Financial Inc:企業の戦略・SWOT・財務分析
    Capitol Federal Financial Inc - Strategy, SWOT and Corporate Finance Report Summary Capitol Federal Financial Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Nexeon MedSystems Inc-医療機器分野:企業M&A・提携分析
    Summary Nexeon MedSystems Inc (Nexeon) is a bioelectronics company that develops and commercializes therapies and devices for the treatment of cardiovascular diseases. The company’s products categories include nanotechnology-based devices, embolic protection systems, local drug and biologic delivery …
  • ChemImage Corp:企業の製品パイプライン分析
    Summary ChemImage Corp (ChemImage) is a molecular chemical imaging company that provides hyperspectral imaging technologies. The company develops molecular chemical imaging devices and data fusion tools for anatomic structure imaging, cancer detection and cardiovascular health assessment. It offers …
  • Guardian Industries Corp.:企業の戦略・SWOT・財務情報
    Guardian Industries Corp. - Strategy, SWOT and Corporate Finance Report Summary Guardian Industries Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • BirchBioMed Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary BirchBioMed Inc (BirchBioMed) is a biomedical company that concentrate on the development, clinical evaluation and commercialization of anti-scarring drugs, autoimmune therapeutics and novel strategies for transplantation. The company’s proprietary and patented lead drug candidate, FS2 is be …
  • New Brunswick Power Corporation:企業の戦略的SWOT分析
    New Brunswick Power Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Spineway SAS (ALSPW):企業の財務・戦略的SWOT分析
    Summary Spineway SAS (Spineway) is a medical device company that manufactures, designs, and commercializes surgical implants and instruments. The company offers products such as thoraco-lumbar, cervical, mini invasive products and other bio materials. Its thoraco-lumbar products include mont blanc d …
  • MRC Systems GmbH:企業の製品パイプライン分析
    Summary MRC Systems GmbH (MRC Systems) is a medical device company that offers medical, electronic and laser optical products. The company’s products include laser beam stabilization, MR compatible cameras, pinprick, cardioman, photoactivation and stereotactic systems. It offers laser beam stabiliza …
  • Diamond Offshore Drilling, Inc.:企業の戦略・SWOT・財務情報
    Diamond Offshore Drilling, Inc. - Strategy, SWOT and Corporate Finance Report Summary Diamond Offshore Drilling, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Alchemia Ltd (ACL):企業の財務・戦略的SWOT分析
    Alchemia Ltd (ACL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆